XSHE
002393
Market cap638mUSD
Oct 09, Last price
14.25CNY
1D
0.78%
1Q
-2.26%
Jan 2017
-65.50%
IPO
-74.91%
Name
Tianjin Lisheng Pharmaceutical Co Ltd
Chart & performance
P/E
10.30
P/S
3.09
EPS
1.38
Div yield, %
2.06%
Shrs. gr., 5y
0.24%
Rev. gr., 5y
4.99%
Revenues
1.39b
+4.23%
Net income
418m
+126.72%
CFO
452m
+411.94%
Dividend
Apr 28, 20260.72 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tianjin Lisheng Pharmaceutical Co.,Ltd. specializes in the manufacturing and distribution of chemical pharmaceutical products. Their extensive catalog features a variety of finished dosage forms, including tablets, hard capsules, dripping pills, freeze-dried powder injections, and water injections, alongside bulk medicines. The company also provides pharmaceutical intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. Headquartered in Tianjin, China, the firm extends its reach through product exports. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.
Key people
Ping Zhang
Chairman of the Board · since 2022
Jiaying Wang
Chief Financial Officer · since 2022
Jiankang Liang
Deputy General Manager · since 2022
Changfeng Long
Deputy General Manager · since 2025
Shuang Duan
Director · since 2025
Xiaoman Lu
Director · since 2025
Fei Teng
Director · since 2023
Qian Wang
Staff Elected Director · since 2025
Fujun Wang
General Manager, Director · since 2022
Independent Director · since 2022
Dongzhi Wei
Independent Director · since 2025
Mei Zhang
Independent Director · since 2022
Headquarters & legal address
天津市西青经济开发区赛达北一道16号
西青区, TJ 300000
CN
西青区, TJ 300000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑00 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||